PharmiWeb

BioInvent Reports Promising Data from Ongoing Phase 2a study for BI-1808 with KEYTRUDA(R) (pembrolizumab) in Recurrent Ovarian Cancer

ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ovarian cancer (8% ORR in KEYNOTE-100)The combination demonstrated a ...
PharmiWeb

Orum Therapeutics Appoints Chad May as Chief Scientific Officer to Drive Degrader-Antibody Conjugate Innovation and Programs

Orum Therapeutics (Orum or the Company) (KRX: 475830), a biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced the appointment of Chad May, Ph.D., as Chief ...
PharmiWeb

Through High-Profile Ambassadors and Major Partnerships, ZetrOZ Systems Expanded Reach of sam Device in 2025

The leader in sports medicine healing innovations worked with athletes, athletic trainers, physicians and foundations to ...
PharmiWeb

Shareholders Russell Budd and Scott Summy Named to the 2026 Lawdragon Hall of Fame

Baron & Budd President and Managing Shareholder Russell Budd, along with Shareholder and leader of the Environmental ...
PharmiWeb

Middle East Health IT Modernization Is Accelerating But Procurement Is Tightening Around Bilingual Operations, Sovereign Hosting, and Verifiable AI

Black Book Survey of health IT leaders across five high-activity Middle East markets finds sovereignty-compatible architectures and Arabic/English workflow readiness are now pass/fail gates-while AI ...
PharmiWeb

Dr. Mendez Explains How a Dual Approach Using Surgery and SRT Helps Manage Persistent Keloids

The Miami Beach keloid specialist outlines why pairing surgical excision with superficial radiation therapy can reduce recurrence and improve long-term comfort. MIAMI BEACH, FLORIDA / ACCESS Newswire ...
PharmiWeb

Desert Oasis Healthcare Raises Awareness About Mpox with Community Podcast Featuring Local Advocates and Leaders

Desert Oasis Healthcare leads community-wide effort to raise awareness and encourage vaccination amid ongoing mpox concerns. PALM SPRINGS, CALIFORNIA / ACCESS Newswire / December 30, 2025 / Desert ...
PharmiWeb

Biological Therapies for Cancer Global Markets Report 2025-2030: Merck, BMS, Roche, AstraZeneca, Johnson & Johnson, and Novartis Drive Growth Through Pipeline Expansion and ...

The "Biological Therapies for Cancer: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.The global biological therapies market for cancer is expected to grow ...
PharmiWeb

Nanocoatings Global Market Data Report 2025: Advances Driven by R&D Investments From PPG Industries, BASF, AkzoNobel, 3M, and Nanophase Technologies - ResearchAndMarkets.com

Global Market Data Report" has been added to ResearchAndMarkets.com's offering.The global market for nanocoating is projected to grow from an estimated $15.3 billion in 2025 to reach $33.2 billion by ...
PharmiWeb

Successful Medical Writing from Protocol to CTD Training Course: Understand International Guidelines and Standards (Mar 23rd - Mar 24th, 2026) - ResearchAndMarkets.com

The "Successful Medical Writing - from Protocol to CTD Training Course (Mar 23rd - Mar 24th, 2026)" training has been added to ResearchAndMarkets.com's offering.Success in the pharmaceutical industry ...
PharmiWeb

Contract Manufacturing of Medical Devices Global Markets Report 2025-2030: Growth Driven by Aging Populations, Rising Chronic Disease Burden, and OEM Shift Toward ISO- and FDA ...

The "Contract Manufacturing of Medical Devices: Global Markets" report has been added to ResearchAndMarkets.com's offering.The global market for contract manufacturing of medical devices is estimated ...
PharmiWeb

Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance

Expects full-year 2026 LINZESS® U.S. net sales of $1.125 to $1.175 billion; total revenues of $450 to $475 million and adjusted EBITDA of greater than $300 million -- Ended Q4 2025 with greater than ...